Health care education, delivery, and qualityReal-world Evaluation of Asthma Control and Treatment (REACT): Findings from a national Web-based survey
Section snippets
Greenfield Online
Greenfield Online is a primary research company that maintains global research panels for the purpose of executing research studies for nonprofit and for-profit companies, government agencies, and academic organizations. The Greenfield Online panel is among the largest Web-based survey cohorts in the world, containing nearly 4 million participants in the United States.5 Members voluntarily opt into Greenfield Online and are recruited from a diverse pool of sources, including Internet portals,
Univariate analysis
A total of 1812 patients were included in this study; of these patients, 809 (45%) had controlled asthma, and 1003 (55%) had uncontrolled asthma. Demographics and disease characteristics for these patients are shown in Table II. Patients with controlled and uncontrolled asthma were similar with regard to age, race/ethnicity, and type of residence. A higher proportion of female than male patients was seen in both groups, but among male patients, a higher proportion was in the uncontrolled group.
Discussion
To our knowledge, the REACT study is the first to assess the prevalence of uncontrolled asthma in the United States in a nationally representative sample of asthma patients taking standard asthma medications. It is also the first study to use multivariable analyses to examine factors associated with uncontrolled disease in a nationally representative sample of treated American asthma patients. Because patients with more severe asthma confer the highest economic burden in asthma care,12, 13 we
References (42)
- et al.
Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting
Chest
(2006) - et al.
Development of the asthma control test: a survey for assessing asthma control
J Allergy Clin Immunol
(2004) - et al.
A comprehensive study of the direct and indirect costs of adult asthma
J Allergy Clin Immunol
(2003) - et al.
Significant variability in response to inhaled corticosteroids for persistent asthma
J Allergy Clin Immunol
(2002) - et al.
Effects of montelukast and beclomethasone on airway function and asthma control
J Allergy Clin Immunol
(2002) - et al.
Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists
J Allergy Clin Immunol
(2006) - et al.
The Asheville Project: long-term clinical, humanistic, and economic outcomes of a community-based medication therapy management program for asthma
J Am Pharm Assoc (Wash)
(2006) - et al.
Managing severe asthma
J Allergy Clin Immunol
(2006) - et al.
Severity, control, and responsiveness in asthma
J Allergy Clin Immunol
(2006) - et al.
Asthma variability in patients previously treated with beta2-agonists alone
J Allergy Clin Immunol
(2003)
Advances in adult and pediatric asthma
J Allergy Clin Immunol
Severity assessment in asthma: an evolving concept
J Allergy Clin Immunol
Relationship between airway obstruction and respiratory symptoms in adult asthmatics
Chest
Guidelines for the diagnosis and management of asthma: update on selected topics 2002
Internet based marketing research: a serious alternative to traditional research methods?
Marketing Intell Plann
Epidemiology, beyond the basics
A dictionary of epidemiology
Cited by (0)
Supported by Genentech, Inc, South San Francisco, Calif.
Disclosure of potential conflict of interest: S. P. Peters has consulting arrangements with and is on the speakers' bureau for Genentech and Novartis. C. A. Jones has consulting arrangements with Genentech, Merck, Sanofi-Aventis, and AstraZeneca; has received grant support from Genentech and Merck; and is on the speakers' bureau for Genentech, Merck, Sanofi-Aventis, and AstraZeneca. T. Haselkorn has consulting arrangements with Genentech. D. R. Mink is employed by Ovation Research Group, which receives grant support from Genentech. D. J. Valacer owns stock in Genentech and General Electric and is employed by Genentech. S. T. Weiss has consulting arrangements with Glaxo-Wellcome, Roche Pharmaceuticals, Millennium Pharmaceuticals, Genentech, Schering-Plough, Variageics, Genome Therapeutics, and Merck Frost and has received grant support from Glaxo-Wellcome, AstraZeneca, and Pfizer.